Cryo Cell International R&D Spending Growth & History (CCEL)
Cryo Cell International's r&d spending was $376,263 for fiscal 2025.
View full Cryo Cell International company overviewCryo Cell International annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-11-30 | $376,263 | −$866,273 | −69.72% |
| 2024 | 2024-11-30 | $1.2M | $71,080 | +6.07% |
| 2023 | 2023-11-30 | $1.2M | $786,667 | +204.44% |
| 2022 | 2022-11-30 | $384,789 | $334,919 | +671.58% |
| 2021 | 2021-11-30 | $49,870 | $26,019 | +109.09% |
| 2020 | 2020-11-30 | $23,851 | −$6,294 | −20.88% |
| 2019 | 2019-11-30 | $30,145 | −$61,700 | −67.18% |
| 2018 | 2018-11-30 | $91,845 | $50,680 | +123.11% |
| 2017 | 2017-11-30 | $41,165 | −$11,932 | −22.47% |
| 2016 | 2016-11-30 | $53,097 | $7,317 | +15.98% |
| 2015 | 2015-11-30 | $45,780 | −$18,587 | −28.88% |
| 2014 | 2014-11-30 | $64,367 | $28,199 | +77.97% |
| 2013 | 2013-11-30 | $36,168 | −$73,472 | −67.01% |
| 2012 | 2012-11-30 | $109,640 | −$74,407 | −40.43% |
| 2011 | 2011-11-30 | $184,047 | $51,056 | +38.39% |
| 2010 | 2010-11-30 | $132,991 | — | — |
Cryo Cell International quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-05-31 | $99,781 | −$31,930 | −24.24% |
| Q1 2026 | 2026-02-28 | $65,761 | −$32,382 | −32.99% |
| Q4 2025 | 2025-11-30 | $84,784 | −$219,845 | −72.17% |
| Q3 2025 | 2025-08-31 | $61,625 | −$132,308 | −68.22% |
| Q2 2025 | 2025-05-31 | $131,711 | −$109,374 | −45.37% |
| Q1 2025 | 2025-02-28 | $98,143 | −$404,746 | −80.48% |
| Q4 2024 | 2024-11-30 | $304,629 | −$139,179 | −31.36% |
| Q3 2024 | 2024-08-31 | $193,933 | −$150,199 | −43.65% |
| Q2 2024 | 2024-05-31 | $241,085 | −$63,597 | −20.87% |
| Q1 2024 | 2024-02-29 | $502,889 | $424,055 | +537.91% |
| Q4 2023 | 2023-11-30 | $443,808 | $367,407 | +480.89% |
| Q3 2023 | 2023-08-31 | $344,132 | $263,860 | +328.71% |
| Q2 2023 | 2023-05-31 | $304,682 | $223,786 | +276.63% |
| Q1 2023 | 2023-02-28 | $78,834 | −$68,386 | −46.45% |
| Q4 2022 | 2022-11-30 | $76,401 | $45,962 | +151.00% |
| Q3 2022 | 2022-08-31 | $80,272 | $70,268 | +702.40% |
| Q2 2022 | 2022-05-31 | $80,896 | $77,659 | +2399.10% |
| Q1 2022 | 2022-02-28 | $147,220 | $141,030 | +2278.35% |
| Q4 2021 | 2021-11-30 | $30,439 | $23,379 | +331.15% |
| Q3 2021 | 2021-08-31 | $10,004 | $8,756 | +701.60% |
| Q2 2021 | 2021-05-31 | $3,237 | −$6,584 | −67.04% |
| Q1 2021 | 2021-02-28 | $6,190 | $468 | +8.18% |
| Q4 2020 | 2020-11-30 | $7,060 | −$9,804 | −58.14% |
| Q3 2020 | 2020-08-31 | $1,248 | −$1,192 | −48.85% |
| Q2 2020 | 2020-05-31 | $9,821 | $4,864 | +98.12% |
| Q1 2020 | 2020-02-29 | $5,722 | −$162 | −2.75% |
| Q4 2019 | 2019-11-30 | $16,864 | −$10,054 | −37.35% |
| Q3 2019 | 2019-08-31 | $2,440 | −$19,794 | −89.03% |
| Q2 2019 | 2019-05-31 | $4,957 | −$24,327 | −83.07% |
| Q1 2019 | 2019-02-28 | $5,884 | −$7,525 | −56.12% |
| Q4 2018 | 2018-11-30 | $26,918 | $9,435 | +53.97% |
| Q3 2018 | 2018-08-31 | $22,234 | $22,008 | +9738.05% |
| Q2 2018 | 2018-05-31 | $29,284 | $20,444 | +231.27% |
| Q1 2018 | 2018-02-28 | $13,409 | −$1,207 | −8.26% |
| Q4 2017 | 2017-11-30 | $17,483 | −$1,162 | −6.23% |
| Q3 2017 | 2017-08-31 | $226 | −$13,554 | −98.36% |
| Q2 2017 | 2017-05-31 | $8,840 | −$3,148 | −26.26% |
| Q1 2017 | 2017-02-28 | $14,616 | $5,932 | +68.31% |
| Q4 2016 | 2016-11-30 | $18,645 | $5,336 | +40.09% |
| Q3 2016 | 2016-08-31 | $13,780 | $3,828 | +38.46% |
| Q2 2016 | 2016-05-31 | $11,988 | $1,457 | +13.84% |
| Q1 2016 | 2016-02-29 | $8,684 | −$3,304 | −27.56% |
| Q4 2015 | 2015-11-30 | $13,309 | −$515 | −3.73% |
| Q3 2015 | 2015-08-31 | $9,952 | −$7,900 | −44.25% |
| Q2 2015 | 2015-05-31 | $10,531 | −$7,792 | −42.53% |
| Q1 2015 | 2015-02-28 | $11,988 | −$2,380 | −16.56% |
| Q4 2014 | 2014-11-30 | $13,824 | $3,781 | +37.65% |
| Q3 2014 | 2014-08-31 | $17,852 | $9,713 | +119.34% |
| Q2 2014 | 2014-05-31 | $18,323 | $11,258 | +159.35% |
| Q1 2014 | 2014-02-28 | $14,368 | $3,447 | +31.56% |
| Q4 2013 | 2013-11-30 | $10,043 | −$11,131 | −52.57% |
| Q3 2013 | 2013-08-31 | $8,139 | −$57,907 | −87.68% |
| Q2 2013 | 2013-05-31 | $7,065 | −$776 | −9.90% |
| Q1 2013 | 2013-02-28 | $10,921 | −$3,658 | −25.09% |
| Q4 2012 | 2012-11-30 | $21,174 | $5,642 | +36.33% |
| Q3 2012 | 2012-08-31 | $66,046 | $13,810 | +26.44% |
| Q2 2012 | 2012-05-31 | $7,841 | −$72,816 | −90.28% |
| Q1 2012 | 2012-02-29 | $14,579 | −$21,043 | −59.07% |
| Q4 2011 | 2011-11-30 | $15,532 | — | — |
| Q3 2011 | 2011-08-31 | $52,236 | $33,340 | +176.44% |
| Q2 2011 | 2011-05-31 | $80,657 | — | — |
| Q1 2011 | 2011-02-28 | $35,622 | — | — |
| Q3 2010 | 2010-08-31 | $18,896 | — | — |
Cryo Cell International r&d spending trends
Over the last five fiscal years, Cryo Cell International's r&d spending increased from $23,851 to $376,263, a change of $352,412. The latest reported quarter, Q2 2026, shows $99,781.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cryo Cell International source filings ↗